ADVANCED ASTHMACONTROLCLINICAL TRIAL
A study on the efficacy of a new monoclonal antibody for patients with severe eosinophilic asthma in New York City.
Study Overview
Severe eosinophilic asthma affects a significant subset of asthma patients who continue to experience frequent exacerbations despite standard controller therapy. This clinical research study evaluates the safety and efficacy of a novel monoclonal antibody designed to target specific inflammatory pathways, potentially reducing exacerbations and improving overall asthma control.
Duration
48-56 Weeks
Target Group
Adults 18-75
Participants must meet the following criteria to be eligible for the study:
- Adults 18-75 years of age
- Physician-diagnosed asthma for at least 12 months
- Current use of medium to high-dose inhaled corticosteroids
- Experiencing at least 2 asthma exacerbations in the past year
- Elevated eosinophil count on recent blood test
- Non-smoker or ex-smoker (quit at least 6 months ago)
- Willing to comply with study visits and procedures
- Provide written informed consent
Apply Now
See if you qualify for this study
Participant Safety is Our Priority
Ethical Oversight
All studies are reviewed and approved by an Institutional Review Board (IRB) to ensure participant safety and rights.
Informed Consent
We provide clear, detailed information about the study before you decide to participate, and you can withdraw at any time.
Expert Monitoring
Participants receive regular health check-ups and are closely monitored by our team of medical professionals.